Research - Since our initial report on Pharmacyclics (PCYC) on February 11, shares of the oncology company have returned almost 52%. Pharmacyclics’ relative underperformance to the NASDAQ … Continue Reading
Read nowInsights - It’s New Year’s Eve. This year flew past – and so did biotech. The NASDAQ Biotechnology Index (NBI) will end the year up 60%, while … Continue Reading
Read nowInsights - Amgen’s PCSK9 inhibitor, evolucumab (AMG145) met its co-primary endpoints in a phase 3 trial: the percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week … Continue Reading
Read nowInsights - On Monday after the close, Cempra (CEMP) updated investors on its pipeline progress. We saw no major surprises and consider the update net-neutral, if not –positive. Read … Continue Reading
Read nowResearch - Although the stock is getting away from us as we await feedback from the company (more below), for those not already involved, Progenics (PGNX) is … Continue Reading
PremiumInsights - An experimental drug from Novartis (NVS) designed to treat a bone marrow cancer met its primary goal in a phase 3 study. In an earlier … Continue Reading
Read nowInsights - Eli Lilly and Company (LLY) on Thursday said it would not seek approval for edivoxetine, an experimental drug to treat major depression, after it failed … Continue Reading
Read now
